(Q33574139)

28 July 2017

title

A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate (English)

1 reference

28 July 2017

1 reference

Dhaval K Shah

1

1 reference

28 July 2017

Lindsay E King

2

1 reference

28 July 2017

Xiaogang Han

3

1 reference

28 July 2017

Jo-Ann Wentland

4

1 reference

28 July 2017

Yanhua Zhang

5

1 reference

28 July 2017

Judy Lucas

6

1 reference

28 July 2017

Nahor Haddish-Berhane

7

1 reference

28 July 2017

Alison Betts

8

1 reference

28 July 2017

Mauricio Leal

9

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 March 2014

1 reference

28 July 2017

1 reference

28 July 2017

volume

16

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

452-463

1 reference

Maturing antibody-drug conjugate pipeline hits 30.

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Factors determining antibody distribution in tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Determination of CD4 antigen density on cells: role of antibody valency, avidity, clones, and conjugation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Tumor uptake as a function of tumor mass: a mathematic model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Cell and environment interactions in tumor microregions: the multicell spheroid model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

A mechanistic compartmental model for total antibody uptake in tumors

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Theoretic criteria for antibody penetration into solid tumors and micrometastases.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Pharmacokinetic model-predicted anticancer drug concentrations in human tumors

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012047

Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24578215

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The pharmacologic basis for antibody-auristatin conjugate activity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24578215

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1208/S12248-014-9576-9

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference